#384 - Special episode — Obicetrapib: The CETP inhibitor with cardiovascular benefits and potential Alzheimer's prevention

Welcome back to The Drive; I’m Peter Attia, and our mission here—across the podcast, site, and newsletter—is to translate longevity science responsibly and ad‑free, thanks to our members.

Today’s a special deep dive into a single drug that has me cautiously excited: obicetrapib, a CETP inhibitor with fresh data that could matter for cardiovascular disease and, intriguingly, Alzheimer’s.

Alzheimer’s research can feel like whiplash, so I’m threading optimism with restraint while I unpack what this class does, why earlier versions stumbled, and what’s new here.

Quick primer: APOB particles like LDL move cholesterol and drive atherosclerosis, while HDL built on APOA1 supports reverse cholesterol transport; CETP swaps cholesterol esters from HDL for triglycerides in LDL, so blocking CETP raises HDL cholesterol and lowers LDL cholesterol.

History first: torcetrapib boosted deaths via off‑target blood pressure effects; dalcetrapib raised HDL but didn’t cut APOB; evacetrapib’s APOB drop was too small over too short a time; anacetrapib mildly reduced events but lingered in fat, and the program was shelved.

Obicetrapib looks different because it delivers large LDL cholesterol reductions on top of statins and ezetimibe, meaningful APOB cuts, big HDL rises, and about a one‑third decline in Lp(a), with early signals of metabolic neutrality or better.

In the phase three BROADWAY trial—very high‑risk patients already on maximal therapy—adding obicetrapib further lowered LDL cholesterol by roughly thirty percent and APOB by the mid‑teens, while HDL more than doubled and Lp(a) dropped substantially.

Regulatory note: Europe can approve on validated biomarkers, so launch there could be in the back half of twenty twenty‑six; the United States likely waits for PREVAIL’s cardiovascular outcomes, so timing will lag.

Why this might touch the brain: the CNS runs its own lipid economy with ApoE, and the ApoE4 protein is worse at moving cholesterol, raising oxidative stress, inflammation, and amyloid burden over decades.

CETP inhibition increases circulating APOA1 and small, functional HDL that can cross the blood‑brain barrier in limited amounts, potentially improving cholesterol efflux and ferrying antioxidants, while systemic APOB lowering supports cerebrovascular health—effects that could matter most in ApoE4.

BROAdWAY’s pre‑specified biomarker sub‑study tracked plasma p‑tau two seventeen over one year in patients with cardiovascular disease but no cognitive impairment and stratified by ApoE genotype.

Headline: obicetrapib blunted the rise in p‑tau two seventeen overall, with a stronger signal in ApoE4 carriers; in the small ApoE4/4 subgroup, p‑tau two seventeen fell on drug while it rose on placebo, and NFL, GFAP, p‑tau one eighty‑one, and the A‑beta forty‑two to forty ratio all moved in favorable directions.

Caveats matter: these are biomarkers, not cognition; follow‑up was only twelve months; the ApoE4/4 sample was small; and the precise mechanism remains a hypothesis, even if biologically coherent.

What I want next is a prevention trial enriched for ApoE4, cognitively normal adults in mid‑to‑late life, with sensitive cognitive endpoints, serial biomarkers, imaging, and multi‑year follow‑up.

Net‑net, I’m optimistic but measured: even for heart disease alone, the lipid effects look meaningful, and the Alzheimer’s biomarker signal—especially in ApoE4—adds real intrigue.

Thanks for listening; show notes are at peterattiaMD.com, and you can find me on YouTube, Instagram, and Twitter at peterattiaMD; this is general information, not medical advice—please talk with your clinician—and my full disclosures live on the site.